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Novel crystalline polymorph of Baloxavir marboxil and process for
preparation thereof
Field of the Invention:
5

The present invention provides novel crystalline polymorph of Baloxavir marboxil
comprising Baloxavir marboxil compound of formula-1 and Methylparaben compound of
formula-2 and process for preparation thereof.

10

Formula-1

Formula-2

Background of the Invention:
({(12aR)-12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl}oxy)methyl
methyl carbonate, commonly known as Baloxavir marboxil is an antiviral polymerase acidic
15

(PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza.
Baloxavir marboxil has been approved by USFDA on October 24, 2018 and by PMDA (The
Pharmaceuticals and Medical Devices Agency, Japan) on February 23, 2018.
US8987441B2 and US10392406B2 describes Baloxavir marboxil, its analogs and
processes for their preparation.

20

US10759814B2 describes three crystalline polymorphs of Baloxavir marboxil namely
form-I, form-II, form-III and processes for their preparation.
WO2020181025A1 describes six crystalline polymorphs of Baloxavir marboxil
namely form-BM1, form-BM2, form-BM3, form-BM4, form-BM5, form-BM6 and
amorphous form and also describes processes for their preparation.

25

CN111875619A describes new crystal form of Baloxavir marboxil and processes for
its preparation.
1
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CN111961064A describes ‘α’ crystal form of Baloxavir marboxil and its process for
preparation.
CN111377944 A describes two crystalline polymorphs of Baloxavir marboxil namely
form-A, form-B and processes for their preparation.
5

Still, there is a significant need in the art to develop novel polymorph of Baloxavir
marboxil.
The present inventors after significant efforts have surprisingly found novel
crystalline polymorph of Baloxavir marboxil comprising Baloxavir marboxil and
Methylparaben.

10
Brief description of the invention:
The first embodiment of the present invention is to provide a novel crystalline
polymorph of Baloxavir marboxil comprising Baloxavir marboxil and Methylparaben.

15

The second embodiment of the present invention is to provide a process for the
preparation of novel crystalline polymorph of Baloxavir marboxil comprising Baloxavir
marboxil and Methylparaben.

Brief Description of the Drawing:
20

Figure-1: Illustrates the PXRD pattern of novel crystalline polymorph of Baloxavir marboxil
comprising Baloxavir marboxil and Methylparaben.

Detailed description of the Invention:
The first embodiment of the present invention is to provide a novel crystalline
25

polymorph of Baloxavir marboxil comprising Baloxavir marboxil and Methylparaben, which
is herein designated as form-R.
The novel crystalline form-R of Baloxavir marboxil of the present invention is
characterized by its PXRD pattern having peaks at 4.0, 7.9 and 11.0 ± 0.2° of 2θ values.

2
https://www.tdcommons.org/dpubs_series/5069

3

Thirumalai Rajan et al.: Novel Crystalline Polymorph Of Baloxavir Marboxil And Process For

The crystalline form-R of Baloxavir marboxil of the present invention is further
characterized by its PXRD pattern having peaks at 11.4, 12.0 and 17.9 ± 0.2° of 2θ values.
The crystalline form-R of Baloxavir marboxil of the present invention is further
characterized by its PXRD pattern as illustrated in figure-1.
5
The second embodiment of the present invention provides a process for the
preparation of novel crystalline form-R of Baloxavir marboxil comprising Baloxavir
marboxil and Methylparaben. The said process comprising;
a)

providing a solution of Baloxavir marboxil and Methylparaben in a solvent at a suitable
temperature,

10

b) obtaining novel crystalline form-R of Baloxavir marboxil.
An aspect of the present invention provides a process for the preparation of
crystalline polymorph of Baloxavir marboxil comprising Baloxavir marboxil and
15

Methylparaben. The said process comprising;
a)

providing a solution of Baloxavir marboxil and Methylparaben in a solvent at a suitable
temperature,

b) obtaining crystalline polymorph of Baloxavir marboxil.
20

The solvent in step-a) is selected from chloro solvents such as dichloromethane,
chloroform, carbon tetrachloride or their mixtures; and the temperature ranges from about
25°C to about 100°C.
The solution of step-a) of the above process can be optionally filtered to make it
particle free.

25

In an aspect of the present invention, the solution of step-a) of the above process can
be optionally treated with charcoal to remove the colour/to clarify the solution.

In one aspect of the present invention, the solution in step-a) of the above described
process can be provided by dissolving Baloxavir marboxil and Methylparaben in a solvent.
30
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The crystalline polymorph of Baloxavir marboxil in step-b) can be obtained by
removal of the solvent from the mixture by various techniques. The techniques include but
not limited to decantation, filtration, evaporation, distillation, cooling the reaction mixture to
a lower temperature, holding the mixture for sufficient time to precipitate the solid followed
5

by removal of the solvent by any of the above techniques.

In an aspect of the second embodiment, the said crystalline polymorph is prepared by
adding a second solvent to a solution comprising Baloxavir marboxil and Methylparaben in a
solvent, filtration of the precipitated solid followed by drying the solid.
10
Wherein, the second solvent is selected from hydrocarbon solvents. In one aspect, the
second solvent is preferably n-heptane.
The solvent may be removed optionally under reduced pressures, at temperatures less
15

than about 100°C, less than about 60°C, less than about 40°C, less than about 20°C, less than
about 0°C, less than about -20°C, less than about -40°C, less than about -60°C or at less than
about -80°C.

The first aspect of the second embodiment of the present invention provides a process
20

for the preparation of crystalline polymorph of Baloxavir marboxil comprising Baloxavir
marboxil and Methylparaben. The said process comprising;
a)

providing a solution of Baloxavir marboxil and Methylparaben in dichloromethane,

b) evaporation of the solvent to provide crystalline polymorph of Baloxavir marboxil.

25

The second aspect of the second embodiment of the present invention provides a
process for the preparation of novel crystalline polymorph of Baloxavir marboxil comprising
Baloxavir marboxil and Methylparaben. The said process comprising;
a)

providing a solution of Baloxavir marboxil and Methylparaben in dichloromethane,

b) combining the solution with n-heptane to provide crystalline polymorph of Baloxavir
30

marboxil.
4
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The Baloxavir marboxil compound of formula-1 which is used as the input in the
above process for the preparation of novel crystalline form-R of Baloxavir marboxil of the
present invention can be synthesized by any of the processes known in the art.
Methylparaben which is used as the input in the above process can be obtained from
5

any commercial sources available.
The novel crystalline form-R of compound of formula-1 of the present invention is
useful for the preparation of various pharmaceutical compositions formulated in a manner
suitable for the route of administration to be used where at least a portion of compound of
formula-1 is present in the composition in particular polymorphic form mentioned.

10

The third embodiment of the present invention provides the use of novel crystalline
form-R of compound of formula-1 of the present invention for the preparation of
pharmaceutical formulations.
The fourth embodiment of the present invention provides a pharmaceutical
composition comprising novel crystalline form-R of compound of formula-1 of the present

15

invention and at least one pharmaceutically acceptable excipient.
The fifth embodiment of the present invention provides a method of treating a patient
in need thereof comprising administering to the said patient a therapeutically effective
amount of novel crystalline form-R of compound of formula-1 of the present invention.
The novel crystalline form-R of compound of formula-1 produced by the process of

20

the present invention may have particle size distribution of D90 less than about 400 µm,
preferably less than about 300 µm, more preferably less than about 200 µm. In one aspect of
the present invention, the novel crystalline form-R of compound of formula-1 may have
particle size distribution of D90 less than about 100 µm, preferably less than about 50 µm.
The crystalline compound of formula-1 produced by the process of the present

25

invention can be further micronized or milled to get desired particle size to achieve desired
solubility profile based on different forms of pharmaceutical composition requirements.
Techniques that may be used for particle size reduction includes but not limited to single or
multi-stage micronization using cutting mills, pin/cage mills, hammer mills, jet mills,
fluidized bed jet mills, ball mills and roller mills. Milling/micronization may be performed

30

before drying or after drying of the product.
5
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P-XRD Method of Analysis:
The PXRD analysis of compound of formula-1 of the present invention was carried
out by using BRUKER/D8 ADVANCE diffractometer using CuKα radiation of wavelength
1.5406A° and at a continuous scan speed of 0.03°/min.
5
The best mode of carrying out the present invention is illustrated by the below
mentioned example. This example is provided as illustration only and hence should not be
construed as limitation to the scope of the invention.

10

Example:
Example-1: Preparation of novel crystalline form-R of Baloxavir marboxil comprising
Baloxavir marboxil and Methylparaben
Baloxavir marboxil (1.0 gm) and Methylparaben (0.266 gm) were dissolved in
dichloromethane (5 ml) at 25-30°C. The solution was held at 25-30°C for 3 hr. Evaporated

15

the solvent, collected the solid and dried to get the title compound.
The PXRD pattern of the obtained compound is shown in figure-1.
Yield: 1.05 gm.
Example-2: Preparation of crystalline form-R of Baloxavir marboxil comprising

20

Baloxavir marboxil and Methylparaben
A mixture of Baloxavir marboxil (5 gm), Methylparaben (1.33 gm) and
dichloromethane (25 ml) was stirred for 15 min at 25-30°C. n-Heptane (150 ml) was slowly
added to the solution at 25-30°C and stirred for 2 hr 15 min at the same temperature. Filtered
the solid, washed with n-heptane and dried the material to get the title compound.

25

The PXRD pattern of the obtained compound is similar to figure-1.
Yield: 4.8 gm.

30

6
https://www.tdcommons.org/dpubs_series/5069

7

Thirumalai Rajan et al.: Novel Crystalline Polymorph Of Baloxavir Marboxil And Process For

Drawing:

5

Figure-1
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